Seagull Therapeutics

Reprogramming
the Tumor Micro-Environment

About Seagull

SeaGull Therapeutics is focused on reprogramming the Tumor Micro Environment for more effective treatment of solid tumors. SeaGull’s lead project, SGL10060, is a fusion protein based on innovative science from the University of Turin.

Meet our team

Reprogramming the tumor micro environment TME

The TME is where the tumor modifies local structures and cells to protect itself from the body’s own immune system and from therapeutic strategies. By reprograming the TME, we help the body fight the tumor and enhance anti-cancer therapies for improved patient outcomes.

Read our publications

Our protein candidate SGL10060

SGL10060 is fusion protein based on Semaphorin3A and selectively targeting PlexinA4. This protein possesses the anti-tumoral proprieties of Semaphorin3A without the known pro-tumoral traits.

Read More

Team

Ashley Nagle

SeaGull Therapeutics CEO/Chairman,
Domain Strategic & Business Director

More
Ashley is a chemist with an MBA and has spent his career on the business side of science. He has worked with small and large companies, managing contacts and alliances and growing businesses. At Domain Therapeutics, Ashley has identified and closed product and technology deals, and helped to create spin off companies in line with company strategy.

Ashley Nagle

SeaGull Therapeutics CEO/Chairman,
Domain Strategic & Business Director

Close

Stephan Schann

SeaGull Therapeutics R&D Advisor,
Domain R&D Director

More
Stephan has a PhD in Medicinal Chemistry from University of Strasbourg, France. Since 2008, Stephan has led R&D at Domain Therapeutics for both its internal and externalized pipeline. He was involved in the identification of Foliglurax, currently in Phase II development for Parkinson’s disease.

Stephan Schann

SeaGull Therapeutics R&D Advisor,
Domain R&D Director

Close

Pascal Neuville

SeaGull Therapeutics Board,
Domain CEO/CSO

More
Pascal holds a PhD in molecular biology from the University of Strasbourg. He was appointed Assistant Professor at the University of Geneva before joining Transgene SA as an R&D project leader. Soon after its creation, he joined Faust Pharmaceuticals SA as CSO. He founded Domain in 2008 and has been CEO / CSO since.

Pascal Neuville

SeaGull Therapeutics Board,
Domain CEO/CSO

Close

Guido Serini MD, Ph.D

Professor of Clinical Biochemistry and Molecular Biology, University of Turin

More
Guido heads the Laboratory of Cell Adhesion Dynamics of the Candiolo Cancer Institute in Turin, Italy. Over the last 20 years, he studied the role of integrin-mediated cell adhesion in blood vessel formation. He has shown that SEMA3A can be therapeutically reintroduced to inhibit tumor growth and extend survival.

Guido Serini MD, Ph.D

Professor of Clinical Biochemistry and Molecular Biology, University of Turin

Close

Enrico Giraudo Ph.D

Professor of Biochemistry at the Faculty of Pharmacy, University of Turin

More
Enrico leads the Transgenic Mouse Models laboratory at the Candiolo Cancer Institute in Turin. Over the last 20 years he has investigated the role of the tumor microenvironment in regulating metastatic growth. He has shown that Sema3A is able to overcome resistance to anti-angiogenic therapies, by normalizing tumor vessels and reducing hypoxia.

Enrico Giraudo Ph.D

Professor of Biochemistry at the Faculty of Pharmacy, University of Turin

Close

Luca Tamagnone MD, Ph.D

Professor of Histology at the School of Medicine, Sacred Heart University of Rome

More
Luca was nominated EMBO Young Investigator in 2001, and from 2003 to 2018 led a renowned research laboratory in Cancer Cell Biology at the Candiolo Cancer Institute. He has been at the forefront of research on Semaphorins, identifying fundamental signalling mechanisms and functional activities in normal and cancer cells.

Luca Tamagnone MD, Ph.D

Professor of Histology at the School of Medicine, Sacred Heart University of Rome

Close

About SGL10060

News & Publications